Impact Biomedical corrects merger ratio to 1:1, sets 1-for-12.62 reverse split effective Sept 23

IMPACT BIOMEDICAL INC.

Reverse stock split 1-for-12.62 effective Sept 23, 2026; shares drop from ~107.8M to ~8.5M.
Corrected merger ratio: 1 Zoar share per 1 Impact share after split, replacing incorrect 1-for-4 in Sept 11 release.
Stockholders authorized split Dec 30, 2025 within 1-for-12.48 to 1-for-50 range; CEO fixed ratio at 12.62.
Split aims to support Zoar merger and regain NYSE American continued-listing compliance; no assurance of success.
Transfer agent Equiniti manages exchange; fractional shares rounded up; new CUSIP for IBO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.